This technology can analyse the expression differences and functional specificity of HIF-1α in specific subpopulations such as renal tubular epithelial cells, macrophages, and fibroblasts at the single-cell level (Han et al., 2024), driving the transition of AKI treatment from broad-based interventions to cell type-targeted regulation. This evidence concerns the gene HIF1A and acute kidney injury.